top of page
A L T I T U D E
Life Science Ventures
HOME
ABOUT
PORTFOLIO
Fund IV
Fund III
Fund II
Historical
TEAM
NEWS
CONTACT
More
Use tab to navigate through the menu items.
Companies in the News
Jun 3, 2024
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who...
bottom of page
